Key clinical point: In patients with type 2 diabetes mellitus (T2D) for ≥10 years, metformin use vs no use was significantly associated with a lower risk for any and early age-related macular degeneration (AMD) but not late AMD.
Major finding: A significant association was observed between metformin use and any AMD (adjusted odds ratio [aOR] 0.24) and early AMD (aOR 0.17; both P < .0001), but not late AMD ( P = .0619). Prolonged use (>5 years) and high cumulative dose (>3500 g) of metformin reduced AMD risk ( Ptrend = .0007).
Study details: This retrospective study included 324 patients aged ≥50 years diagnosed with T2D for ≥10 years, of which 209 were metformin users and 115 were metformin nonusers.
Disclosures: This study was funded by Hospital Youth Research Fund of China-Japan
Friendship Hospital and Beijing University of Chemical Technology-China-Japan Friendship Hospital Biomedical Translational Engineering Research Center Joint Fund. The authors declared no competing interests.
Source: Jiang J et al. Association between metformin use and the risk of age-related macular degeneration in patients with type 2 diabetes: A retrospective study. BMJ Open. 2022;12:e054420 (Apr 26). Doi: 10.1136/bmjopen-2021-054420